Drug intelligence / Profile preview

flunoprazine

Development stage: Unknown
Lead developer: Lianyungang Kanion
Modality: Small Molecules
Administration: Oral

Overview

Flunoprazine is a small molecule serotonin receptor modulator developed by Jiangsu Kanion Pharmaceutical for the treatment of mild to moderate Alzheimer's disease. It primarily acts as an agonist at the 5-HT1A receptor and an antagonist at the 5-HT2A receptor. This dual mechanism is intended to enhance cognitive function and potentially address behavioral and psychological symptoms of dementia (BPSD) by modulating serotonergic signaling in the brain. The drug is currently being evaluated in Phase 2 clinical trials in China to assess its efficacy, safety, and pharmacokinetics in patients with Alzheimer's disease.

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on flunoprazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on flunoprazine.

Explore the full profile